News
Morrisons Clinic, the supermarket's online prescription service, has launched the weight-loss jab which has been dubbed 'the ...
Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...
“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...
A new study has found that an anti-obesity drug called tirzepatide, which is sold under the names Mounjaro for diabetes and ...
The Canadian Press on MSN1d
B.C. limits sales of two more diabetes drugs amid off-label use for weight lossBritish Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.
Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...
People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...
Presented by AstraZeneca{beacon} Health Care Health Care The Big Story CMS targets hospitals with site-neutral drug ruleThe ...
Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.
For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...
In postmenopausal women with overweight or obesity receiving tirzepatide, use of MHT is associated with superior weight loss outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results